The information provided in this article is based on a press release statement. In other recent news, Cencora, Inc. has reported notable developments that are of interest to investors. The company has completed the acquisition of Retina Consultants of America for $4.4 billion, which led to an upward revision of its fiscal year 2025 adjusted earnings per share (EPS) guidance. The new EPS range is set between $15.15 and $15.45, an increase from the previous estimate of $14.80 to $15.10. This acquisition is expected to bolster Cencora's position in specialty medical services and enhance its management services organization solutions. Additionally, Leerink Partners has raised Cencora's stock price target to $301 from $287, maintaining an Outperform rating. This adjustment follows Cencora's impressive first-quarter fiscal year 2025 results, which exceeded expectations and resulted in guidance upgrades. The firm's robust performance in the U.S. Healthcare sector continues to drive positive analyst sentiment.